Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835662 | 1.00 | UTS2R (0.58) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835265 | 0.89 | UTS2R (0.73) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835321 | 0.89 | UTS2R (0.73) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835262 | 0.89 | UTS2R (0.73) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835499 | 0.85 | UTS2R (0.80) | UTS2R | |
| SCHEMBL5835680 | 0.85 | UTS2R (0.80) | UTS2R | |
| SCHEMBL5835500 | 0.85 | UTS2R (0.58) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835685 | 0.85 | UTS2R (0.58) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835457 | 0.80 | UTS2R (0.67) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL5835460 | 0.80 | UTS2R (0.67) | UTS2RLMNAHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | claimed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | claimed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | claimed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | disclosed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152906-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885LMNA 3610/4885HTT 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.